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Mannose receptor is critical  
for the development  
of crescentic glomerulonephritis
Chavele et al., J Clin Invest 2010; 120: 1469–1478; doi:10.1172/JCI41560
Crescentic glomerulonephritis (CGN) is frequently associated with 
systemic vasculitis or systemic lupus erythematosus and, despite 
immunosuppression therapy, often leads to end-stage renal disease. 
Multiple components of the immune system, including antibodies, 
complement, and infiltrating lymphocytes, appear to participate in 
its pathogenesis, but macrophages are an absolute requirement for 
its development. In response to chemokines produced after cell-
mediated immune reactions or antibody deposition, macrophages 
migrate to and localize in and around the glomerulus, promoting 
immune injury. Glomerular injury also involves proliferation of 
mesangial cells, and it is likely that interaction between resident 
and infiltrating cells is bidirectional, with mesangial cells influ-
encing the response of infiltrating macrophages. The mannose 
receptor (MR) is a pattern recognition receptor expressed by tissue 
macrophages, mesangial cells, and some endothelial and dendritic 
cells. It is a lectin scavenger receptor, important in clearance of 
microbial and endogenous molecules produced during inflam-
mation and autoantigens implicated in systemic vasculitis, anti-
glomerular basement membrane disease, and CGN. In addition, 
MR binding may enhance Fc-mediated responses, an interesting 
action since it was recently shown that Fc-mediated responses were 
critical in induction of CGN. In a recent publication, Chavele et 
al. used the mouse model of nephrotoxic nephritis to investigate 
the role of the MR in CGN. They induced nephritis in wild-type 
(WT) mice and in mice with deletion of the MR (Mr–/–) and found 
that whereas the former developed renal dysfunction, proteinuria, 
CGN, and severe tubulointerstitial inflammation, Mr–/– mice were 
protected, with preserved renal function and only mild glomerular 
hypercellularity (Figure). Interestingly, although Mr–/– mice were 
protected from CGN, they generated humoral and T-cell responses 
similar to those of WT mice. However, the mice had decreased 
macrophage and mesangial-cell Fc receptor-mediated functions, 
including phagocytosis and Fc-mediated oxygen burst activity. 
In addition, Mr–/– mesangial cells had increased apoptosis, and 
macrophage interaction with apoptotic mesangial cells induced a 
non-inflammatory phenotype. These results demonstrate that the 
MR augments Fc-mediated function and promotes mesangial-cell 
survival and suggest that targeting the MR may provide an alterna-
tive therapeutic approach in CGN.
Juan Oliver
Effects of intensive blood pressure 
control in type 2 diabetes mellitus
ACCORD Study Group, N Engl J Med 2010; 362: 1575–1585; doi:10.1056/
NEJMoa1001286
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
Study randomized 4733 participants with type 2 diabetes mellitus 
to one of two different blood pressure targets to determine whether 
more intensive control of hypertension reduces major cardiovas-
cular events. Intensive therapy targeted a systolic blood pressure 
of less than 120 mm Hg, and standard therapy a systolic pressure 
of less than 140 mm Hg. The study noted the effect of treatment 
target on the composite outcomes of nonfatal myocardial infarc-
tion, nonfatal stroke, or death from cardiovascular causes over the 
mean follow-up of 4.7 years and excluded patients with a serum 
creatinine level of more than 1.5 mg/dl. The treatment strategy 
focused on the goal blood pressure rather than a comparison of 
any particular medications or treatment regimens. Randomized 
participants had a hemoglobin A1c level of 8.3%, a baseline blood 
pressure of 139.2/76.0 mm Hg, and an estimated glomerular fil-
tration rate (eGFR) of 91.6 ml/min overall at baseline. The study 
found no differences between treatment groups in the composite 
primary outcome. The subjects in the intensive-therapy group 
experienced a lower risk of fatal or nonfatal stroke (hazard ratio, 
0.59 and 0.63) with no differences in any other prespecified out-
comes. Small, but statistically great, numbers of participants in the 
intensive-therapy group experienced some potentially blood pres-
sure-related adverse events during follow-up. Seventeen patients 
in this group experienced hypotension, compared with one in the 
standard-therapy group. Twelve versus three patients experienced 
an arrhythmia, nine versus one experienced hyperkalemia, and 
99 versus 52 experienced a fall in eGFR to less than 30 ml/min. 
The median urine albumin-to-creatinine ratio was lower in the 
intensive-therapy group (12.6 versus 14.9), and fewer participants 
experienced macroalbuminuria in the intensive-therapy group (6.6 
versus 8.1%).
While this study was not designed to examine whether inten-
sive control of blood pressure affects cardiovascular outcomes in 
chronic kidney disease (CKD) patients per se, it should be recog-
nized that, in patients with normal or near-normal kidney func-
tion, a lower blood pressure target does not confer a particular 
benefit. Until additional information is available, and while ongo-
ing studies address whether cardiovascular or renal outcomes 
benefit from a lower blood pressure target among patients with 
CKD, we must utilize this information, as well as conclusions from 
the African American Study of Kidney Disease and Hypertension 
Nephrotoxic nephritis in wild-type (WT) (a) and Mr–/– (b) mice. 
Sections stained with periodic acid-Schiff demonstrated CGN (single 
asterisk) and severe tubulointerstitial injury (double asterisk) with 
dilated tubules and cast formation.
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(AASK) trial,1 in the treatment of patients with normal kidney 
function to balance an unknown benefit against the potential for 
a small but increased risk.
Lynda Szczech
1JAMA 2002; 288: 2421–2431.
Circulating mitochondrial DAMPs 
cause inflammatory responses  
to injury
Zhang et al., Nature 2010; 464: 104–107; doi:10.1038/nature08780
A systemic inflammatory response syndrome (SIRS) is observed 
in a number of clinical situations involving serious tissue injury. 
Clinically, the presentation of SIRS closely resembles sepsis, includ-
ing frequent acute deterioration of renal function, yet there is no 
evidence for infection in SIRS. Therefore, investigators have looked 
for triggers of the inflammatory response but have not identified 
any clear candidates so far. In sepsis, microbial pathogen-asso-
ciated molecular patterns (PAMPs) activate innate immuno-
cytes through pattern recognition receptors, thereby initiating 
the inflammatory response. Similarly, cellular injury can release 
endogenous ‘damage’-associated molecular patterns (DAMPs) that 
activate innate immunity. Zhang et al. reasoned that mitochondria 
are evolutionary endosymbionts that were derived from bacteria 
and so might bear bacterial molecular pattern motifs. Such mito-
chondrial molecules would be released upon tissue damage and 
could be recognized by receptors of the innate immune system, 
resulting in a pattern of systemic immune response comparable 
to bacterial sepsis. The authors demonstrated that injury releases 
mitochondrial DAMPs into the circulation with functionally 
important immune consequences. The mitochondrial molecules 
released include formyl peptides and mitochondrial DNA. These 
activate human polymorphonuclear neutrophils (PMNs) through 
formyl peptide receptor-1 and Toll-like receptor 9 (TLR9), respec-
tively. The mitochondrial DAMPs promote PMN Ca2+ flux and 
phosphorylation of mitogen-activated protein kinases, thus lead-
ing to PMN migration and degranulation, in vitro and in vivo. The 
authors also established that circulating mitochondrial DAMPs 
can elicit neutrophil-mediated multiple organ injury in vivo, thus 
mimicking SIRS. On the basis of these observations, the authors 
proposed that cellular disruption by trauma releases mitochon-
drial DAMPs with evolutionarily conserved similarities to bacterial 
PAMPs. In the circulation, these signal through innate immune 
pathways identical to those activated in sepsis, to create a sepsis-
like state. The release of such mitochondrial ‘enemies within’ by 
cellular injury may be a key link between trauma, inflammation, 
and SIRS and, as such, may also contribute to the renal involve-
ment in SIRS.
Detlef Schlöndorff
A CD8+ T cell transcription signature 
predicts prognosis  
in autoimmune disease
McKinney et al., Nat Med 2010; 16: 586–591; doi:10.1038/nm.2130
Despite its many complications, immunosuppressive therapy is the 
norm for patients with severe autoimmune diseases. In patients 
with cancer, gene expression-based biomarkers are starting to 
facilitate individual tailoring of chemotherapy, thereby decreasing 
the use of unneeded drugs and the incidence of complications. To 
examine whether a similar approach could allow individual tailor-
ing of immunosuppressive therapy, McKinney et al. performed 
a transcription profile of purified CD8+ T cells and found that it 
identified two distinct subject subgroups predicting long-term 
prognosis in two autoimmune diseases that frequently affect the 
kidney: antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis and systemic lupus erythematosus (SLE). Despite the 
differences between these two diseases, there was a clear correla-
tion between the specific groups and relapsing episodes of disease 
in both patients with ANCA-associated vasculitis and patients 
with SLE. The researchers found that the subset of genes defining 
the poor prognostic group was enriched for genes involved in the 
interleukin-7 receptor pathway and T-cell receptor signaling and 
those expressed by memory T cells. Moreover, the poor prognos-
tic group was associated with an expanded CD8+ T cell memory 
population. Interestingly, they also identified these subgroups in 
a population of normal subjects. Of potentially great practical 
importance was that detailed analysis of their data revealed that 
the subgroups could be identified by measurement of expres-
sion of only three genes (ITGA2, NOTCH1, and PTPN22, which 
encode integrin α2, notch homolog 1, and protein tyrosine phos-
phatase non-receptor type 2, respectively). This exciting study 
suggests that transcription profiling of CD8+ T cells may allow 
use of immunosuppressive therapy in the group of patients who 
truly need it, sparing patients at low risk of relapse the complica-
tions associated with such therapy.
Juan Oliver
Rats given intravenous mitochondrial DAMPs (MTD) equivalent to 
mitochondria from a 5% liver injury exhibit marked evidence of 
lung injury, as shown by hematoxylin and eosin histology (a, b) and 
4-hydroxy-2-nonenal stain for oxidant injury (c, d).
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